Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PRASHANT G KOSHY

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1982871695
CMS profile
363114
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,627.76

112 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,304.07 108
Travel and Lodging $1,264.29 3
Gift $59.40 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 112 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PRASHANT G KOSHY

NPI 1982871695 · CMS profile ID 363114

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 112 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1982871695?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PRASHANT G KOSHY, NPI 1982871695, CMS profile ID 363114. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 112 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1982871695?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). PRASHANT G KOSHY, NPI 1982871695, CMS profile ID 363114. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 112 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1982871695?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
PRASHANT G KOSHY, NPI 1982871695, CMS profile ID 363114, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 112 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1982871695?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

112 matching records · $3,627.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 112 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 112.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $28.0508/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997681111 CMS
Lilly USA, LLC $9.6908/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032049801 CMS
Lilly USA, LLC $20.3408/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032018035 CMS
Amgen Inc. $13.1808/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020058005 CMS
Dexcom, Inc. $18.3407/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054958469 CMS
Esperion Therapeutics, Inc. $19.3107/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050741051 CMS
Alexion Pharmaceuticals, Inc. $26.6707/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016997109 CMS
Lilly USA, LLC $21.8507/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031949895 CMS
Lilly USA, LLC $29.6607/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032018041 CMS
Novo Nordisk Inc $16.7507/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001576029 CMS
RECORDATI_RARE_DISEASES_INC. $21.7007/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060353117 CMS
Currax Pharmaceuticals LLC $13.6707/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 986432807 CMS
Lilly USA, LLC $26.3207/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032099357 CMS
ABBVIE INC. $18.8507/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997681109 CMS
Amgen Inc. $16.0006/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020057999 CMS
Novo Nordisk Inc $16.9106/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001576089 CMS
Lilly USA, LLC $19.5106/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032099365 CMS
Currax Pharmaceuticals LLC $14.1006/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 986432805 CMS
Amryt Pharma Holdings Ltd $19.3706/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051605777 CMS
ABBVIE INC. $19.7906/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997681107 CMS
MannKind Corporation $19.4906/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056276103 CMS
MannKind Corporation $23.3105/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056276097 CMS
Bayer Healthcare Pharmaceuticals Inc. $24.0605/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000476533 CMS
IBSA Pharma Inc. $14.2205/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999727275 CMS
Novo Nordisk Inc $6.7705/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001575905 CMS
Novo Nordisk Inc $16.9105/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001576077 CMS
Lilly USA, LLC $14.8205/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032076259 CMS
SANOFI-AVENTIS U.S. LLC $26.3705/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050155667 CMS
MannKind Corporation $14.0005/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056276089 CMS
Radius Health, Inc. $17.4905/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024706647 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.1504/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057097593 CMS
Dexcom, Inc. $22.9104/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054958453 CMS
Novo Nordisk Inc $8.6004/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001575919 CMS
Radius Health, Inc. $12.8604/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024706645 CMS
Novo Nordisk Inc $14.7704/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001575961 CMS
Currax Pharmaceuticals LLC $12.9704/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 986432801 CMS
Lilly USA, LLC $22.9904/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031999583 CMS
MannKind Corporation $18.4003/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056276081 CMS
MannKind Corporation $14.3803/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056276075 CMS
Amgen Inc. $18.5303/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020058003 CMS
Corcept Therapeutics $20.7603/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050831405 CMS
Abbott Laboratories $23.8803/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018864821 CMS
Novo Nordisk Inc $23.3203/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001576131 CMS
Lilly USA, LLC $23.4403/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031999589 CMS
Ascendis Pharma Inc $27.9103/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014528483 CMS
Amryt Pharma Holdings Ltd $20.3703/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051605697 CMS
CeQur Corporation $59.0303/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031945013 CMS
Novo Nordisk Inc $14.4603/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001575947 CMS
MannKind Corporation $10.4402/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056276067 CMS
PFIZER INC. $16.4202/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049258089 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,728.57 110
PY2020 $1,446.75 81
PY2021 $2,547.05 147
PY2022 $2,304.45 132
PY2023 $3,627.76 112
PY2024 $3,167.26 155
PY2025 $3,856.90 145

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $503,928.49 9
PY2024 Recipient $14,943.92 3
PY2024 Principal investigator $271,956.18 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

9 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $3,315.00 12/30/2025 Non-covered Recipient Entity
ENDOCRINE IPS PLLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT REDUCTION WITH MACUPATIDE AND ELORALINTIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187882904
Principal investigator 1 Amgen Inc. $63,841.35 06/17/2025 Non-covered Recipient Entity
PLANIT RESEARCH, PLLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246646637
Principal investigator 1 Eli Lilly and Company $4,331.10 04/20/2025 Non-covered Recipient Entity
ENDOCRINE IPS PLLC
A PHASE 2B DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BIMAGRUMAB AND TIRZEPATIDE, ALONE OR IN COMBINATION, TO INVESTIGATE THE EFFICACY AND SAFETY IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187880237
Principal investigator 1 Eli Lilly and Company $1,022.88 02/14/2025 Non-covered Recipient Entity
ENDOCRINE IPS PLLC
A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) No dispute reported 06/30/2026 1187881734
Principal investigator 1 Eli Lilly and Company $4,237.26 01/31/2025 Non-covered Recipient Entity
ENDOCRINE IPS PLLC
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR No dispute reported 06/30/2026 1187882008
Principal investigator 1 Eli Lilly and Company $24.90 01/22/2025 Non-covered Recipient Entity
ENDOCRINE IPS PLLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187882900
Principal investigator 1 Eli Lilly and Company $70,488.00 01/21/2025 Non-covered Recipient Entity
ENDOCRINE IPS PLLC
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR No dispute reported 06/30/2026 1187880917
Principal investigator 1 Eli Lilly and Company $178,045.00 01/07/2025 Non-covered Recipient Entity
ENDOCRINE IPS PLLC
A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) No dispute reported 06/30/2026 1187879029
Principal investigator 1 Eli Lilly and Company $178,623.00 01/07/2025 Non-covered Recipient Entity
ENDOCRINE IPS PLLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187881732